Table 2.
Population characteristics, TCD, OS, and PFS in each arm (arm A: bevacizumab maintenance; arm B: observation arm without treatment during CFIs).
| Arm A: bevacizumab maintenance arm N = 160 | Arm B: no treatment during CFI N = 154 | Overall population N = 314 | |
|---|---|---|---|
| Age (mean, range) | 64.6 (26.9–88.8) | 64.9 (37.4–84.3) | 64.7 (26.9–88.8) |
| Sex, n.% | |||
| Males | 100 (62.5%) | 105 (68.2%) | 205 (65.3%) |
| Females | 60 (37.5%) | 49 (31.8%) | 109 (34.7%) |
| ECOG PS n.% | |||
| 0 | 77 (48.1%) | 75 (48.7%) | 152 (48.4%) |
| 1 | 75 (46.9%) | 70 (45.5%) | 145 (46.2%) |
| ⩾2 | 8 (5.0%) | 9 (5.8%) | 17 (5.4%) |
| TCD [median months (95% CI)] | 15.4 (12.5–17.42) | 17.3 (13.4–23.3) | 15.7 (13.7–18.0) |
| Overall survival [median months (95% CI)] | 22.6 (19.3–25.3) | 22.1 (230.3–25.2) | 22.6 (20.8–24.3) |
| PFS [median months (95% CI)] | 9.2 [8.9; 10.1] | 9.1 [8.0; 9.6] | 9.2 [8.9; 9.6] |
| Duration of CFI, mean. (SD) | 5.1 (4.3) | 4.7 (3.3) | 4.9 (3.9) |
CFI, chemotherapy-free interval; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival; PFS, progression-free survival; SD, standard deviation; TCD, tumor control duration.